Personalizing CLL Treatment Options: Managing Adverse Events Associated With Novel Agents

In this short video, Susan M. O’Brien, MD, compares the adverse event profiles of newer targeted therapies in the treatment of CLL and the optimal management of these adverse events.
Susan M. O'Brien, MD
Released: July 24, 2018 Expiration: No longer available for credit

Related Content

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 27, 2022

Downloadable slideset from a local live webinar developed by lymphoma experts with guidance on the management of indolent lymphomas

Elizabeth Brém, MD Christopher R. Flowers, MD, MS Released: June 21, 2022

Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 20, 2022
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Acerta Pharma, a member of the AstraZeneca Group
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Pharmacyclics LLC, an AbbVie Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings